Abstract
Basal and recombinant human growth hormone (rhGH)-stimulated insulin-like growth factor (IGF-I) levels were studied in 19 insulin-dependent diabetic patients and 4 healthy subjects. Diabetic patients were divided according to glucagon test result into CpN (10 patients without residual beta cell activity) and CpP (9 patients with preserved beta-cell activity) groups, and according to age into three groups (A=21–30 years; B=31–40 years; C=41–50 years). All control subjects belonged to group B. Blood glucose and growth hormone were measured at hourly intervals and IGF-I every 6 h during 24 h before and after 7 days treatment with 4 IU of rhGH given subcutaneously at 8 p.m. The age-related decrease in basal IGF-I levels was evident in both CpN and CpP groups of diabetic patients. IGF-I net increase with rhGH treatment was variable and insignificant in comparison with basal value without age-related differences in CpN diabetics. Progressively larger age-related increases in IGF-I concentrations were observed in CpP diabetic patients. This study indicates impairment of hepatic IGF-I generation capacity in diabetic patients without residual beta-cell activity and the importance of simultaneous actions of portal insulin and GH on hepatic IGF-I production.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Muller EE, Clinical implications of growth hormone feedback mechanisms. Horm Res 33 [Suppl 4]:90–96, 1990
Hansen AP, Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest 49:1467–1478, 1970
Kjeldsen H, Hansen AP, Twenty-four hour serum hormone levels in maturity-onset diabetics. Diabetes 24:977–982, 1975
Herschopf R, Plotnick LP, Kaya K, Benedict GW, Hadji-Georgopoulos A, Margiolis S, Kowarski KA, Short-improvement in glycaemic controls utilising continuous subcutaneous insulin infusion: the effect on 24-hour integrated concentrations of counter regulatory hormones and plasma lipids in insulin dependent diabetes mellitus. J Clin Endorinol Metab 54:504–509, 1982
Arias P, Kerner W, de la Fuente A, Pfeiffer EF, Abnormal growth hormone levels in insulin-dependent patients under continuous subcutaneous insulin infusion and intensified conventional treatment. Acta Endocrinol (Copenh) 107:250–255, 1984
Asplin CM, Faria ACS, Carlsen EC, Ewans WS, Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69:239–245, 1989
Wurzburger MI, Prelevic GM, Sönksen PH, Peric LA, Till S, Morris RW, The effects of improved blood glucose on growth hormone and cortisol secretion in insulin-dependent diabetes mellitus. Clin Endocrinol 32:787–797, 1990
Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, Sherwin RS, Insulin-infusion-pump treament of diabetes: influence of improved metabolic control on plasma somatomedins levels. N Engl J Med 305:303–307, 1981
Horner JM, Kemp SF, Hintz R, Growth hormone and somatomedins in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 53:1148–1153, 1981
Shaper NC, Tamsma JT, Sluiter WJ, Roelse H, Reitsma WD, Doorenbos H, Growth hormone auto regulation in type I diabetes mellitus. Acta Endocrinol (Copenh) 122 [Suppl]:32–39, 1990
Teale JD, Marks V, The measurements of insulin-like growth factor I: clinical application and significance. Ann Clin Biochem 23:413–424, 1986
Wurzburger MI, Prelevic GM, Sönksen PH, Balin-Peric LA, Growth hormone level in patients with type I diabetes is age related. Diabetic Med 10:159–161, 1993
Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming AG, Bain RP, Impaired growth hormone secretion in the adult population. J Clin Invest 67:1361–1369, 1981
Ho KY, Hoffman DM, Physiology of growth hormone (GH) secretion: implication for diagnosis of GH deficiency in adults. In: Laron Z, Butenandt O (eds) Growth hormone replacement therapy in adults—pros and cons. Freund Publishing House, Tel Aviv, pp5–16, 1993
Merimee TJ, Zapf J, Insulin-like growth factors in adult diabetics. In: Martin Spencer E (ed) Insulin-like growth factors—somatomedins. de Gruyter Berlin, pp 295–298, 1983
Amiel SA, Sherwin RS, Hintz RJ, Gertner GC, Press M, Tamborlane WV, Effects of diabetes and its control on insulin-like growth factors in the young subjects with type I diabetes. Diabetes 33:1175–1179, 1984
Merimee TJ, Gardner DF, Zapf J, Froesch ER, Effect of glycaemic control on serum-insulin growth factors in diabetes mellitus. Diabetes 33:790–793, 1984
Rieu M, Binoux M, Serum levels of insulin-like growth factor (IGF) and IGF binding protein in insulin-dependent diabetics during an episode of severe metabolic decompensation and the recovery phase. J Clin Endocrinol Metab 60:781–785, 1985
Wurzburger MI, Prelevic GM, Sönksen PH, Balint-Peric LA, Wheeler M, The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab 77: 267–272, 1993
Lanes L, Recker B, Fort P, Deshitz F, Impaired somatomedins generation test in children with insulin-dependent diabetes mellitus. Diabetes 34:156–160, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wurzburger, M.I., Prelevic, G.M., Sönksen, P.H. et al. Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetol 32, 131–134 (1995). https://doi.org/10.1007/BF00569572
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00569572